695 related articles for article (PubMed ID: 28108243)
41. The prognostic value of BAP1, PBRM1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue markers in localized renal cell carcinoma: A retrospective study of tissue microarrays using immunohistochemistry.
Kim SH; Park WS; Park EY; Park B; Joo J; Joung JY; Seo HK; Lee KH; Chung J
PLoS One; 2017; 12(6):e0179610. PubMed ID: 28654655
[TBL] [Abstract][Full Text] [Related]
42. DNA methylation of CRB3 is a prognostic biomarker in clear cell renal cell carcinoma.
Li P; Liu J; Li J; Liu P
Mol Biol Rep; 2019 Aug; 46(4):4377-4383. PubMed ID: 31147860
[TBL] [Abstract][Full Text] [Related]
43. S100A8 Expression May Have a Prognostic Value in CCRCC Reflecting TNM Staging and Fuhrman Nuclear Grade.
An HJ; Koh HM; Song DH
Anticancer Res; 2019 Sep; 39(9):4681-4685. PubMed ID: 31519567
[TBL] [Abstract][Full Text] [Related]
44. Prognostic significance of two lipid metabolism enzymes, HADHA and ACAT2, in clear cell renal cell carcinoma.
Zhao Z; Lu J; Han L; Wang X; Man Q; Liu S
Tumour Biol; 2016 Jun; 37(6):8121-30. PubMed ID: 26715271
[TBL] [Abstract][Full Text] [Related]
45. High TXNDC5 expression predicts poor prognosis in renal cell carcinoma.
Mo R; Peng J; Xiao J; Ma J; Li W; Wang J; Ruan Y; Ma S; Hong Y; Wang C; Gao K; Fan J
Tumour Biol; 2016 Jul; 37(7):9797-806. PubMed ID: 26810069
[TBL] [Abstract][Full Text] [Related]
46. Prevalence and prognostic value of FBXO11 expression in patients with clear cell renal cell carcinoma.
Fan B; Wang W; Zhang X; Sun M; Wang X; Chen Z; Liu W; Wang Q; Yu N; Li X
BMC Cancer; 2019 Jun; 19(1):534. PubMed ID: 31159774
[TBL] [Abstract][Full Text] [Related]
47. Low Expression of ATM Indicates a Poor Prognosis in Clear Cell Renal Cell Carcinoma.
Ren W; Xue B; Chen M; Liu L; Zu X
Clin Genitourin Cancer; 2019 Jun; 17(3):e433-e439. PubMed ID: 30773312
[TBL] [Abstract][Full Text] [Related]
48. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
[TBL] [Abstract][Full Text] [Related]
49. Identification of early stage recurrence endometrial cancer biomarkers using bioinformatics tools.
Besso MJ; Montivero L; Lacunza E; Argibay MC; Abba M; Furlong LI; Colas E; Gil-Moreno A; Reventos J; Bello R; Vazquez-Levin MH
Oncol Rep; 2020 Sep; 44(3):873-886. PubMed ID: 32705231
[TBL] [Abstract][Full Text] [Related]
50. Vimentin over-expression and carbonic anhydrase IX under-expression are independent predictors of recurrence, specific and overall survival in non-metastatic clear-cell renal carcinoma: a validation study.
Ingels A; Hew M; Algaba F; de Boer OJ; van Moorselaar RJ; Horenblas S; Zondervan P; de la Rosette JJ; Pilar Laguna Pes M
World J Urol; 2017 Jan; 35(1):81-87. PubMed ID: 27207480
[TBL] [Abstract][Full Text] [Related]
51. Positive intratumoral chemokine (C-C motif) receptor 8 expression predicts high recurrence risk of post-operation clear-cell renal cell carcinoma patients.
Fu Q; Chang Y; Zhou L; An H; Zhu Y; Xu L; Zhang W; Xu J
Oncotarget; 2016 Feb; 7(7):8413-21. PubMed ID: 26716905
[TBL] [Abstract][Full Text] [Related]
52. Low level of PDZ domain containing 1 (PDZK1) predicts poor clinical outcome in patients with clear cell renal cell carcinoma.
Zheng J; Wang L; Peng Z; Yang Y; Feng D; He J
EBioMedicine; 2017 Feb; 15():62-72. PubMed ID: 27993630
[TBL] [Abstract][Full Text] [Related]
53. B-MYB-p53-related relevant regulator for the progression of clear cell renal cell carcinoma.
Nientiedt M; Müller K; Nitschke K; Erben P; Steidler A; Porubsky S; Popovic ZV; Waldbillig F; Mühlbauer J; Kriegmair MC
J Cancer Res Clin Oncol; 2021 Jan; 147(1):129-138. PubMed ID: 32951068
[TBL] [Abstract][Full Text] [Related]
54. High-level S100A6 promotes metastasis and predicts the outcome of T1-T2 stage in clear cell renal cell carcinoma.
Lyu X; Li H; Ma X; Li X; Gao Y; Ni D; Shen D; Gu L; Wang B; Zhang Y; Zhang X
Cell Biochem Biophys; 2015 Jan; 71(1):279-90. PubMed ID: 25120023
[TBL] [Abstract][Full Text] [Related]
55. High CLEC-2 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma.
Xiong Y; Liu L; Xia Y; Wang J; Xi W; Bai Q; Qu Y; Long Q; Xu J; Guo J
Oncotarget; 2016 Sep; 7(39):63661-63668. PubMed ID: 27564117
[TBL] [Abstract][Full Text] [Related]
56. Dysregulation of β-catenin is an independent predictor of oncologic outcomes in patients with clear cell renal cell carcinoma.
Krabbe LM; Westerman ME; Bagrodia A; Gayed BA; Darwish OM; Haddad AQ; Khalil D; Kapur P; Sagalowsky AI; Lotan Y; Margulis V
J Urol; 2014 Jun; 191(6):1671-7. PubMed ID: 24291548
[TBL] [Abstract][Full Text] [Related]
57. Low NR3C2 levels correlate with aggressive features and poor prognosis in non-distant metastatic clear-cell renal cell carcinoma.
Zhao Z; Zhang M; Duan X; Deng T; Qiu H; Zeng G
J Cell Physiol; 2018 Oct; 233(10):6825-6838. PubMed ID: 29693713
[TBL] [Abstract][Full Text] [Related]
58. Lymphovascular invasion in clear cell renal cell carcinoma--association with disease-free and cancer-specific survival.
Belsante M; Darwish O; Youssef R; Bagrodia A; Kapur P; Sagalowsky AI; Lotan Y; Margulis V
Urol Oncol; 2014 Jan; 32(1):30.e23-8. PubMed ID: 23428539
[TBL] [Abstract][Full Text] [Related]
59. Increased expression of colony stimulating factor-1 is a predictor of poor prognosis in patients with clear-cell renal cell carcinoma.
Yang L; Wu Q; Xu L; Zhang W; Zhu Y; Liu H; Xu J; Gu J
BMC Cancer; 2015 Feb; 15():67. PubMed ID: 25886010
[TBL] [Abstract][Full Text] [Related]
60. RAB27A is an independent prognostic factor in clear cell renal cell carcinoma.
An HJ; Song DH; Koh HM; Ko GH; Lee JH; Kim DC; Yang JW; Kim MH; Seo DH; Jang SM; Lee JS
Biomark Med; 2019 Mar; 13(4):239-247. PubMed ID: 30661368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
